Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

We recently caught up with Nick Karls, director of compliance at Holmes Murphy and Associates, and Nathan Cassin, pharmacy ...

“Companies are realizing that investing stateside can provide more control and resilience to the drug supply chain,” says ...

SmithRx's 2024 growth comes with continued validation of its transparent, 100% pass-through model, which helps significantly lower costs for employer clients. Paired with Connect 360's innovative ...

CMS recently issued a statement saying that it's continuing the Medicare Drug Price Negotiation Program but is leaving the ...

As clinical trial complexity, duration, and cost continue to rise, life sciences companies are turning to data to help them ...

Q4 2024 Earnings Call Transcript February 11, 2025 Royalty Pharma plc misses on earnings expectations. Reported EPS is ...

Dong-A Socio Holdings posts 82.1 billion won profit, sales rise to 1.33 trillion won Dong-A Socio Holdings achieves ...

The decision comes in the wake of changes to Novartis' organisational structure, including the ... of upcoming generic launches and some big biosimilar products not due to reach the market until ...

Strategies to optimize structures A detailed knowledge of antibody structure and activity now ... of regulatory pathways to register biosimilar antibodies might be another way to decrease ...

With patents on originator biologic medicines beginning to expire in the United States, there’s a growing opportunity for biosimilars to enter the market as alternative therapeutic options at ...

Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...